Abstract: Provided is a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as defined herein for use in the treatment or prevention of a Dirofilaria infection in a mammal, The compounds are also for use in the treatment or prevention of diseases or conditions caused by a Dirofilaria infection in a mammal. Also described are corresponding methods of treating or preventing a Dirofilaria infection in a mammal.

Abstract: Modular storage systems include load sensors disposed beneath or in association with platforms. The load sensors are pulse-sampled for signals corresponding to loads at time intervals, rather than continuously, in order to conserve electrical power. An item associated with a transaction is identified based on a change in the loads, as determined from the pulse-sampled signals. The platforms are aligned at horizontal or non-horizontal angles, and photovoltaic power sources with banks of photovoltaic cells are mounted to front edges of the platforms. When a user reaches over one of the photovoltaic cells to access an item on a platform, a level of power or voltage generated by the photovoltaic cell is diminished. The item closest to the photovoltaic cell having the diminished power or voltage, or a customer that accessed the item, may be identified accordingly.

Abstract: The present invention relates to compounds of Formulae (I) and (II) as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae (I) and (II), and to the use of compounds of Formulae (I) and (II) in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

Abstract: The present invention relates to a combination therapeutic product comprising one or more respiratory electron transport chain inhibitors and a cytochrome bd inhibitor, as defined herein, or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising the combination therapeutic product and to the use of the combination therapeutic product in the treatment of mycobacterial infections, such as tuberculosis.

Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.

Abstract: The present invention relates to a combination therapeutic product comprising one or more respiratory electron transport chain inhibitors and a cytochrome bd inhibitor, as defined herein, or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising the combination therapeutic product and to the use of the combination therapeutic product in the treatment of mycobacterial infections, such as tuberculosis.

Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.